Stanley Capital Partners (SCP) has exited its portfolio company Noden Pharma DAC (Noden Pharma) to a European business in the specialist pharmaceutical sector.

SCP exits the business having achieved a COC of 6.7x and an IRR of 151%. The sale of Noden Pharma marks the first exit since SCP was formed.
 
Headquartered in Dublin, Noden Pharma is a global speciality pharmaceutical company focused on the manufacturing of prescription medicines across a variety of cardiovascular treatments for patients who are intolerant to mainstream treatments.